SEASTAR MEDICAL HOLDING CORP
ICUNASDAQTrading Snapshot
- Day Range
- $3.64 – $3.71
- 52-Week Range
- $2.07 – $7.35
- Volume
- $3.08B
- Avg Volume
- $3.07B
- Shares Outstanding
- 2.8M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $615,000
- P/E Ratio
- -0.9
- P/S Ratio
- 5.7x
- EPS (TTM)
- $-3.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4113.6%
Why Investors Own ICU
- ✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 59% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SEASTAR MEDICAL HOLDING CORP
ICU
StockOtter · stockotter.spaceAbout SEASTAR MEDICAL HOLDING CORP
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
SEASTAR MEDICAL HOLDING CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ICU price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SEASTAR MEDICAL HOLDING CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.